# Matthew H. Kulke

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/matthew-h-kulke/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,516 |
| Field | Neuroendocrine Tumor Research Advances |
| h-index | 83 |
| i10-index | 214 |
| Last Known Institution | Boston Medical Center |
| OpenAlex ID | https://openalex.org/A5017947396 |
| ORCID iD | https://orcid.org/0000-0001-8556-3977 |
| Works | 420 |

## Researcher papers

Showing 12 of 14.

- [Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
- [Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-for-the-treatment-of-advanced-non-functional-neuroendocrine-tumours/)
- [Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial](https://scholariq.org/papers/daily-oral-everolimus-activity-in-patients-with-metastatic-pancreatic/)
- [Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors](https://scholariq.org/papers/consensus-guidelines-for-the-management-and-treatment-of-neuroendocrine-tumors/)
- [NANETS Treatment Guidelines](https://scholariq.org/papers/nanets-treatment-guidelines/)
- [Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors](https://scholariq.org/papers/phase-ii-study-of-temozolomide-and-thalidomide-in-patients-with-metastatic/)
- [Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial](https://scholariq.org/papers/health-related-quality-of-life-in-patients-with-progressive-midgut/)
- [NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018](https://scholariq.org/papers/nccn-guidelines-insights-neuroendocrine-and-adrenal-tumors-version-2-2018/)
- [Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors](https://scholariq.org/papers/appropriate-use-criteria-for-somatostatin-receptor-pet-imaging-in-neuroendocrine/)
- [The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas](https://scholariq.org/papers/the-nanets-consensus-guidelines-for-the-diagnosis-and-management-of-poorly/)
- [Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer](https://scholariq.org/papers/genome-wide-association-study-identifies-multiple-susceptibility-loci-for/)
- [Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome](https://scholariq.org/papers/telotristat-ethyl-a-tryptophan-hydroxylase-inhibitor-for-the-treatment-of/)

## Researcher topics

- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Boston Medical Center](https://scholariq.org/institutions/boston-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.